These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 29348105)

  • 21. Parcopa: a rapidly dissolving formulation of carbidopa/levodopa.
    Med Lett Drugs Ther; 2005 Jan; 47(1201):12. PubMed ID: 15706700
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of the pharmacokinetics of an oral extended-release capsule formulation of carbidopa-levodopa (IPX066) with immediate-release carbidopa-levodopa (Sinemet(®)), sustained-release carbidopa-levodopa (Sinemet(®) CR), and carbidopa-levodopa-entacapone (Stalevo(®)).
    Hsu A; Yao HM; Gupta S; Modi NB
    J Clin Pharmacol; 2015 Sep; 55(9):995-1003. PubMed ID: 25855267
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-Term Treatment with Extended-Release Carbidopa-Levodopa (IPX066) in Early and Advanced Parkinson's Disease: A 9-Month Open-Label Extension Trial.
    Waters CH; Nausieda P; Dzyak L; Spiegel J; Rudzinska M; Silver DE; Tsurkalenko ES; Kell S; Hsu A; Khanna S; Gupta S
    CNS Drugs; 2015 Apr; 29(4):341-50. PubMed ID: 25895021
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immediate-release and controlled-release carbidopa/levodopa in PD: A 5-year randomized multicenter study.
    Van Horn G; Schiess MC
    Neurology; 2000 Jul; 55(1):156-7. PubMed ID: 10891940
    [No Abstract]   [Full Text] [Related]  

  • 25. Controlled-release carbidopa/levodopa (Sinemet 50/200 CR4): clinical and pharmacokinetic studies.
    LeWitt PA; Nelson MV; Berchou RC; Galloway MP; Kesaree N; Kareti D; Schlick P
    Neurology; 1989 Nov; 39(11 Suppl 2):45-53; discussion 59. PubMed ID: 2685650
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Physicians' experience with RYTARY (carbidopa and levodopa) extended-release capsules in patients who have Parkinson disease.
    Silver DE; Trosch RM
    Neurology; 2016 Apr; 86(14 Suppl 1):S25-35. PubMed ID: 27044647
    [TBL] [Abstract][Full Text] [Related]  

  • 27. New strategies in dopaminergic therapy of Parkinson's disease: the use of a controlled-release formulation. London, England, April 28 and 29, 1989. Proceedings.
    Neurology; 1989 Nov; 39(11 Suppl 2):1-106. PubMed ID: 2586761
    [No Abstract]   [Full Text] [Related]  

  • 28. Pharmacokinetics of Rytary
    Mittur A; Gupta S; Modi NB
    Clin Pharmacokinet; 2017 Sep; 56(9):999-1014. PubMed ID: 28236251
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical experience with controlled-release carbidopa/levodopa in Parkinson's disease.
    Pahwa R; Busenbark K; Huber SJ; Michalek D; Hubble JP; Koller WC
    Neurology; 1993 Apr; 43(4):677-81. PubMed ID: 8469321
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacoscintigraphic and pharmacokinetic evaluation on healthy human volunteers of sustained-release floating minitablets containing levodopa and carbidopa.
    Goole J; Van Gansbeke B; Pilcer G; Deleuze P; Blocklet D; Goldman S; Pandolfo M; Vanderbist F; Amighi K
    Int J Pharm; 2008 Nov; 364(1):54-63. PubMed ID: 18778758
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Night-time bioavailability of levodopa/carbidopa/entacapone is higher compared to controlled-release levodopa/carbidopa.
    Kuoppamäki M; Sauramo A; Korpela K; Vahteristo M; Kailajärvi M; Lehtinen T; Ellmén J
    Int J Clin Pharmacol Ther; 2010 Nov; 48(11):756-60. PubMed ID: 20979935
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Chaotropic agents in liquid chromatographic method development for the simultaneous analysis of levodopa, carbidopa, entacapone and their impurities.
    Vemić A; Jančić Stojanović B; Stamenković I; Malenović A
    J Pharm Biomed Anal; 2013 Apr; 77():9-15. PubMed ID: 23354116
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Controlled-release levodopa/carbidopa. I. Sinemet CR3 treatment of response fluctuations in Parkinson's disease.
    Cedarbaum JM; Breck L; Kutt H; McDowell FH
    Neurology; 1987 Feb; 37(2):233-41. PubMed ID: 3808304
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Advances in levodopa therapy for Parkinson disease: Review of RYTARY (carbidopa and levodopa) clinical efficacy and safety.
    Dhall R; Kreitzman DL
    Neurology; 2016 Apr; 86(14 Suppl 1):S13-24. PubMed ID: 27044646
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacokinetics of levodopa/carbidopa delivered from gastric-retentive extended-release formulations in patients with Parkinson's disease.
    Chen C; Cowles VE; Sweeney M; Stolyarov ID; Illarioshkin SN
    J Clin Pharmacol; 2012 Jul; 52(7):1069-77. PubMed ID: 21610205
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Carbidopa/Levodopa ER Capsules (Rytary(®), Numient™): A Review in Parkinson's Disease.
    Greig SL; McKeage K
    CNS Drugs; 2016 Jan; 30(1):79-90. PubMed ID: 26692288
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacokinetic model of oral levodopa and role of carbidopa in parkinsonian patients.
    Mizutani Y; Okada Y; Ogawa M; Hasegawa T; Nabeshima T
    Biol Pharm Bull; 1995 Dec; 18(12):1729-37. PubMed ID: 8787797
    [TBL] [Abstract][Full Text] [Related]  

  • 38. IPX066: a novel carbidopa-levodopa extended-release formulation.
    Hauser RA
    Expert Rev Neurother; 2012 Feb; 12(2):133-40. PubMed ID: 22288668
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of controlled-release carbidopa/levodopa on motor performance in advanced Parkinson's disease.
    Rondot P; Ziegler M; Aymard N; Teinturier A
    Neurology; 1989 Nov; 39(11 Suppl 2):74-7; discussion 95. PubMed ID: 2586765
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Enteral feeding in Parkinson's patients receiving levodopa/carbidopa intestinal gel.
    Bove F; Bentivoglio AR; Naranian T; Fasano A
    Parkinsonism Relat Disord; 2017 Sep; 42():109-111. PubMed ID: 28676196
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.